Live News EQUITY FLASH L impact Oct 26, 2026, 11:08 AM UTC Genmab Reports Median Survival in Phase 2 Petosemtamab Combination Study Genmab reported median survival with a petosemtamab combination in a Phase 2 study. GENMAB SquawkNews Desk